mTOR/NF-κB signaling pathway protects hippocampal neurons from injury induced by intermittent hypoxia in rats

Int J Neurosci. 2021 Oct;131(10):994-1003. doi: 10.1080/00207454.2020.1766460. Epub 2020 May 14.

Abstract

Objective: To expound the roles of mTOR and NF-kB signaling pathway in intermittent hypoxia (IH)-induced damage of hippocampal neurons.

Methods: For rat experiments, mTOR inhibitor (Rapamycin, Rapa) and NF-κB signaling inhibitor (ammonium pyrrolidine dithiocarbamate, PDTC) were applied to inhibit mTOR and NF-κB signaling, respectively. For neuron experiments, hippocampal neurons from rat were successfully cultured. Different concentrations of Rapa and PDTC were added to the cultured hippocampal neurons. Rat or primary hippocampal neurons were exposed to normoxic or IH conditions after administration of Rapa and PDTC. The effects of Rapa and PDTC administration on learning and memory ability of rats and hippocampal injury after IH exposure were assayed by Morris water maze and H&E staining. Electron microscope was utilized to examine primary hippocampal neuron ultrastructure changes after IH exposure and Rapa or PDTC administration. The expressions of NF-κB-p65, IκBα, IKKβ, BDNF, TNF-α, IL-1β, PSD-95 and SYN in hippocampal neurons were examined.

Results: Compared with normal control rats or neurons, IH-treated group had elevated expression levels of NF-kB, TNF-α and IL-1β and suppressed expression level of BDNF, PSD-95 and SYN. These results were reversed upon pre-treatment with Rapa and PDTC. Furthermore, IκBα and IKKβ expressions were down-regulated in IH group. No notable difference was manifested in PDTC pre-treatment group, while a prominent increase was shown after Rapa pre-administration.

Conclusion: The administration of PDTC and Rapa could prevent IH-induced hippocampal neuron impairment, indicating that inhibition of the mTOR and NF-κB pathway may likely act as a therapeutic target for obstructive sleep apnea.

Keywords: Hippocampal neurons; NF-kB/mTOR signaling pathway; PDTC; Rapa; intermittent hypoxia; obstructive sleep apnea.

MeSH terms

  • Animals
  • Antioxidants / pharmacology*
  • Cells, Cultured
  • Disease Models, Animal
  • Hippocampus / drug effects
  • Hippocampus / metabolism*
  • Hypoxia / drug therapy
  • Hypoxia / metabolism*
  • Male
  • NF-kappa B / antagonists & inhibitors
  • NF-kappa B / metabolism*
  • Neurons / drug effects
  • Neurons / metabolism*
  • Protein Kinase Inhibitors / pharmacology*
  • Pyrrolidines / pharmacology*
  • Rats
  • Rats, Wistar
  • Signal Transduction / drug effects
  • Signal Transduction / physiology
  • Sirolimus / pharmacology*
  • Sleep Apnea, Obstructive / drug therapy
  • Sleep Apnea, Obstructive / metabolism
  • TOR Serine-Threonine Kinases / antagonists & inhibitors
  • TOR Serine-Threonine Kinases / metabolism*
  • Thiocarbamates / pharmacology*

Substances

  • Antioxidants
  • NF-kappa B
  • Protein Kinase Inhibitors
  • Pyrrolidines
  • Thiocarbamates
  • pyrrolidine dithiocarbamic acid
  • mTOR protein, rat
  • TOR Serine-Threonine Kinases
  • Sirolimus